Kynexis Funding Round

8/19/2026

Venture Equity

$47,000,000

Series A

The financing will support close-out activities for the Phase 2 proof-of-concept study of KYN-5356 for cognitive impairment associated with schizophrenia (CIAS), preparations for registrational clinical development in CIAS, and continued advancement towards additional cognitive disorders, including Alzheimer's disease.

Private & Independent

Biopharmaceutical

Gooimeer 2-35
Naarden, 1411 DC
The Netherlands

Undisclosed

Kynexis is advancing a potential first-in-class approach to restore cognitive function for people living with brain diseases. The company is developing KYN-5356, a first-in-class KAT-II inhibitor designed to lower elevated kynurenic acid (KYNA), a key biological driver of cognitive impairment in disorders including schizophrenia and Alzheimer's disease. By targeting this novel pathway, KYN-5356 is designed to restore the signaling required for normal cognitive function. KYN-5356 is currently being evaluated in a Phase 2 clinical trial for cognitive impairment associated with schizophrenia (CIAS), with development expanding into Alzheimer's disease. At Kynexis, we are driven by a simple purpose: improving cognition to enable a better life for people with brain diseases.